Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer has been approved by the US FDA making it the first biosimilar to be approved in the US for the treatment of cancer. Mvasi has been approved for the treatment of adult patients with certain colorectal, lung, brain, kidney and cervical cancers.